Patents by Inventor Hans J. Johansson

Hans J. Johansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10751645
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 25, 2020
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J Johansson, Jean-Luc Maloisel
  • Publication number: 20180154281
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 7, 2018
    Applicant: GE Healthcare BioProcess R&D AB
    Inventors: CARINA ENGSTRAND, ANNIKA FORSS, GUNNAR GLAD, BO-LENNART JOHANSSON, HANS J JOHANSSON, JEAN-LUC MALOISEL
  • Patent number: 9878266
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: January 30, 2018
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J Johansson, Jean-Luc Maloisel
  • Publication number: 20170247407
    Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.
    Type: Application
    Filed: May 16, 2017
    Publication date: August 31, 2017
    Applicant: GE Healthcare BioProcess R&D AB
    Inventors: Hans J. Johansson, Ronnie Palmgren
  • Patent number: 9657055
    Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: May 23, 2017
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Hans J. Johansson, Ronnie Palmgren
  • Patent number: 9296791
    Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: March 29, 2016
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Sophia Hober, Hans J. Johansson
  • Patent number: 9266041
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: February 23, 2016
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Bo-Lennart Johansson, Jean-Luc Maloisel, Hans J. Johansson, Asa Ek, Maria Holm, Jafar Saidzadeh
  • Publication number: 20150328563
    Abstract: The invention discloses a process for chromatographic separation of at least one target biomolecule from at least one contaminant, comprising the steps of: a) providing an axial chromatography column comprising a consolidated bed of separation matrix particles, where the consolidated bed is confined between a bottom support net and a movable top adaptor; b) separating a target biomolecule from at least one contaminant on the column; c) raising the adaptor by at least 10% of the height of the consolidated bed; d) flowing a cleaning liquid upwards through the bed under conditions sufficient to liquefy the bed, and; e) repacking the matrix particles of the liquefied bed to create a consolidated bed and lowering the adaptor such that it contacts the packed bed and optionally compresses it, and; f) separating a target biomolecule from at least one contaminant on the column.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 19, 2015
    Applicant: GE Healthcare Bio-Sciences AB
    Inventors: Karol Lacki, Hans J. Johansson
  • Publication number: 20150073128
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: CARINA ENGSTRAND, ANNIKA FORSS, GUNNAR GLAD, BO-LENNART JOHANSSON, HANS J JOHANSSON, JEAN-LUC MALOISEL
  • Patent number: 8895710
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: November 25, 2014
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
  • Publication number: 20140329995
    Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 6, 2014
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Hans J. Johansson, Ronnie Palmgren
  • Patent number: 8354510
    Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 15, 2013
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Sophia Hober, Hans J. Johansson
  • Publication number: 20120149875
    Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the adsorbed immunoglobulin containing proteins; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins. The method improves upon previous separation methods being that each of the ligands consists essentially of a monomer or dimer SpA or protein Z or a functional variant thereof.
    Type: Application
    Filed: January 11, 2010
    Publication date: June 14, 2012
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Hans J. Johansson, Anders Ljunglof, Ronnie Palmgren
  • Publication number: 20110266225
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Application
    Filed: June 13, 2011
    Publication date: November 3, 2011
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: BO-LENNART JOHANSSON, JEAN-LUC MALOISEL, HANS J. JOHANSSON, ASA EK, MARIA HOLM, JAFAR SAIDZADEH
  • Publication number: 20110118442
    Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Application
    Filed: January 4, 2011
    Publication date: May 19, 2011
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: CARINA ENGSTRAND, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
  • Patent number: 7867784
    Abstract: The present invention relates to a chromatography ligand defined by the following formula (I) R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: January 11, 2011
    Assignee: GE Healthcare Bio-Science AB
    Inventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
  • Patent number: 7750129
    Abstract: The present invention relates to a process for the purification of antibodies from one or more impurities in a liquid, which process comprises contacting said liquid with a first chromatography resin comprised of a support to which multi-modal ligands have been immobilised to adsorb the antibodies to the resin, wherein each multi-modal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system; adding an eluent to release the antibodies from the resin; and contacting the eluate so obtained with a second chromatography resin. In one embodiment, the ring-forming atoms of the aromatic or heteroaromatic entity are selected from the group consisting of C, S and O, and the cation exchanging group is a weak cation exchanger.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: July 6, 2010
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Bo-Lennart Johansson, Hans J. Johansson, Anna Grönberg, Jean-Luc Maloisel, Nicolas Thevenin
  • Patent number: 7714112
    Abstract: The present invention relates to a method of separating antibodies from other compound(s) in a liquid sample, wherein a mobile phase comprising said sample is contacted with a multi-modal separation matrix to adsorb undesired compounds while the antibodies remain free in the liquid, wherein the multi-modal separation matrix comprises first groups, which are capable of interacting with negatively charged sites of the target compounds, and second groups, which are capable of at least one interaction other than charge-charge interaction with said target compounds. The invention also relates to a chromatography column packed with the above-described multi-modal separation matrix and a filter having such multi-modal groups adsorbed to its surface.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: May 11, 2010
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
  • Patent number: 7709209
    Abstract: The present invention relates to the use of an alkali-stable protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: May 4, 2010
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Sophia Hober, Hans J. Johansson, Tomas Bjorkman
  • Publication number: 20100022760
    Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Application
    Filed: September 29, 2009
    Publication date: January 28, 2010
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: SOPHIA HOBER, Hans J. Johansson